Clinical Study on Improving Exercise Capacity in Chronic Obstructive Pulmonary Disease Through Smart IoT-Remote Home Breathing Guidance

Clinical Study on Improving Exercise Capacity in Chronic Obstructive Pulmonary Disease Through Smart IoT-Remote Home Breathing Guidance: A Multicenter, Randomized, Controlled Clinical Trial

This study aims to evaluate the clinical efficacy of breath-guided improvement of COPD exercise ability, establish a breath-guided rehabilitation program of intelligent iot and remote home, improve COPD exercise ability, reduce acute exacerbation, and form high-quality clinical evidence.

Chronic obstructive pulmonary disease (COPD) is the most common chronic airway disease in China. Based on the digital management platform, 548 patients with COPD in stable stage were selected as the research objects. A multi-center, randomized, controlled clinical trial design was adopted to scientifically evaluate the clinical efficacy of breath-guided improvement of COPD exercise ability and reveal its mechanism of action. A breath-guided rehabilitation program based on intelligent iot and remote home was established and promoted to improve exercise ability and reduce acute exacerbation. To form high-quality clinical evidence, and realize tracking management, real-time evaluation and effect evaluation throughout rehabilitation.

Inclusion Criteria:

• Patients with COPD in stable stage
• Patients with grade 2 to 4 lung function
• Age 40~80 years old
• Be able to use smart phones, computers and other devices independently or with the help of family members during home training
• Volunteer for treatment and sign an informed consent form

Exclusion Criteria:

• Pregnant or lactating women and patients with recent pregnancy plans
• Delirious, dementia, all kinds of mental illness
• Tumor patients who have undergone resection, radiation, and chemotherapy within 5 years
• Patients with severe osteoarthropathy or osteoporosis, unstable fractures
• Patients with severe visual impairment that cannot be improved or who have epilepsy or vertigo and cannot use VR devices
• Patients with progressive neuromuscular disease
• Patients with pulmonary abscess, pulmonary interstitial fibrosis, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism and other pulmonary diseases
• Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, grade 3 or above cardiac function, stroke, cerebral hemorrhage, etc.)
• Patients with severe liver disease (cirrhosis, portal hypertension and bleeding caused by esophageal and gastric varices, etc.) and severe kidney disease (dialysis, kidney transplantation, etc.)
• Participants who were participating in other clinical trials within 1 month prior to enrollment
• People who stay in bed for a long time for various reasons